Sally Barrington
#86,957
Most Influential Person Now
Researcher
Sally Barrington's AcademicInfluence.com Rankings
Sally Barringtoncomputer-science Degrees
Computer Science
#10694
World Rank
#11245
Historical Rank
Machine Learning
#4877
World Rank
#4934
Historical Rank
Artificial Intelligence
#5245
World Rank
#5316
Historical Rank
Database
#7668
World Rank
#7964
Historical Rank
Download Badge
Computer Science
Sally Barrington's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Sally Barrington Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sally Barrington is a professor of positron emission tomography Imaging and National Institute for Health Research research professor at King's College London , England, United Kingdom. She joined KCL in 1993.
Sally Barrington's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 (2014) (1949)
- Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) (1153)
- Imaging biomarker roadmap for cancer studies (2016) (718)
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. (2016) (549)
- Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. (2015) (540)
- Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma (2010) (318)
- Detection of lymphoma in bone marrow by whole-body positron emission tomography. (1998) (313)
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. (2016) (303)
- International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers (2013) (277)
- Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography. (2012) (222)
- The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale (2014) (219)
- PET scanning and the human immunodeficiency virus-positive patient. (1997) (217)
- PET/CT for Therapy Response Assessment in Lymphoma (2009) (206)
- Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL (2016) (204)
- PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. (2013) (202)
- Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. (1996) (185)
- FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas (2017) (177)
- PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. (2016) (137)
- Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus (2012) (133)
- Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses (2011) (132)
- Limitations of PET for imaging lymphoma (2003) (127)
- Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology (2008) (122)
- Retrospective data-driven respiratory gating for PET/CT (2008) (120)
- Guidelines for the management of diffuse large B‐cell lymphoma (2016) (116)
- Guidelines for the use of imaging in the management of patients with myeloma (2017) (98)
- Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid (1997) (95)
- Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma (2018) (95)
- Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients (1999) (94)
- Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012 (2014) (93)
- Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial (2012) (91)
- Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism (1999) (91)
- Speech-related visualization of laryngeal muscles with fluorine-18-FDG. (1996) (88)
- Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. (2018) (83)
- Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. (1998) (82)
- Interictal regional slow activity in temporal lobe epilepsy correlates with lateral temporal hypometabolism as imaged with18FDG PET: neurophysiological and metabolic implications (1998) (81)
- Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden (2019) (81)
- Evidence-based indications for the use of PET-CT in the United Kingdom 2016. (2016) (79)
- The impact of PET scanning on management of paediatric oncology patients (2004) (78)
- Guidelines for the first line management of classical Hodgkin lymphoma (2014) (74)
- FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. (2007) (69)
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy (2013) (69)
- Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. (2011) (66)
- When should FDG‐PET be used in the modern management of lymphoma? (2014) (65)
- Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma (2002) (61)
- Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014 (2015) (60)
- Clinical Value of “Ictal” FDG‐Positron Emission Tomography and the Routine Use of Simultaneous Scalp EEG Studies in Patients with Intractable Partial Epilepsies (1998) (59)
- The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma (2014) (56)
- The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. (2017) (55)
- 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH‐secreting neuroendocrine tumours (2006) (54)
- Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology (2008) (54)
- Focal abnormalities detected by 18FDG PET in epileptic encephalopathies. (1996) (52)
- Positron Emission Tomography in Imaging Spinal Cord Tumors (2000) (42)
- Analysis of loco-regional failures in head and neck cancer after radical radiation therapy. (2015) (40)
- Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma (2010) (39)
- Pentavalent 99Tcm-DMSA imaging in patients with bone metastases. (1997) (39)
- Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma (1998) (37)
- Atlas of Clinical Positron Emission Tomography (1999) (37)
- The role of positron emission tomography in the management of colorectal cancer (2004) (36)
- Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium (2020) (35)
- A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography (1997) (35)
- The effects of standardization and reference values on patient classification for spine and femur dual-energy X-ray absorptiometry (2005) (34)
- Positron emission tomography in the management of lymphomas. (2002) (32)
- Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. (2019) (31)
- Applications of positron emission tomography in neuro-oncology: a clinical approach. (2014) (31)
- Imaging in lung cancer. (1996) (30)
- Interictal 18FDG PET findings in temporal lobe epilepsy with déjà vu. (1999) (29)
- Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients? (2018) (29)
- Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. (2002) (28)
- Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B‐cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement (2016) (28)
- Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. (1995) (28)
- 18F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma (2016) (28)
- RESPONSE‐ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE‐ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). (2017) (27)
- Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD (2008) (27)
- 18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality? (2017) (26)
- Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid (1996) (26)
- Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. (1995) (25)
- Guidelines for the use of PET-CT in children. (2008) (24)
- PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas (2016) (24)
- Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B‐cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group‐37 study (2017) (24)
- Report of the 6th International Workshop on PET in lymphoma (2017) (24)
- Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma (2020) (24)
- All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting (2018) (24)
- Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism (2008) (23)
- Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study (2020) (22)
- The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. (2021) (22)
- PET-CT in the UK: current status and future directions. (2016) (21)
- Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index (2022) (20)
- FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study (2020) (20)
- Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. (2021) (20)
- Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma (2017) (19)
- The role of PET in first-line treatment of Hodgkin lymphoma. (2021) (19)
- Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium (2004) (18)
- CAN BASELINE PET‐CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033) (2017) (18)
- Imaging of abdominal infection using 99mTc stannous fluoride colloid labelled leukocytes (2002) (16)
- A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL (2019) (16)
- Interictal estimation of intracranial seizure onset in temporal lobe epilepsy (2014) (15)
- The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper (2019) (15)
- FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? (2016) (15)
- CXCR2 Inhibition – a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial (2017) (14)
- Effect of Bayesian-penalized likelihood reconstruction on [13N]-NH3 rest perfusion quantification (2016) (13)
- Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY) (2020) (13)
- Unilateral diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and multiple carcinoids treated with surgical resection. (2010) (13)
- Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study (2018) (13)
- PET-Directed Therapy for Hodgkin's Lymphoma. (2015) (12)
- Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. (2020) (12)
- A survey of dual‐energy X‐ray absorptiometry (DEXA) normal reference ranges used within the UK and their effect on patient classification (1995) (12)
- The new EANM paediatric dosage card — does it conform to ALARA for PET/CT? (2007) (12)
- Is it all cerebral toxoplasmosis? (2012) (11)
- Moving the goalposts while scoring―the dilemma posed by new PET technologies (2021) (10)
- Imaging follicular lymphoma using positron emission tomography with [(18)F]fluorodeoxyglucose: to what purpose? (2012) (10)
- Three Cases of Hereditary Tyrosinaemia Type 1: Neuropsychiatric Outcomes and Brain Imaging Following Treatment with NTBC. (2017) (10)
- OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F‐FDG PET‐CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG (2017) (10)
- Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial (2019) (9)
- Opportunistic infection and nuclear medicine. (2009) (8)
- Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study (2018) (8)
- Clinical uses of PET in neurology. (2000) (8)
- Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? (2018) (8)
- Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first‐line chemotherapy (2019) (8)
- Comparing approaches to correct for respiratory motion in NH3 PET-CT cardiac perfusion imaging (2013) (8)
- 63. RCP guidelines on radiation protection following radio-iodine therapy for thyrotoxicosis: Are they appropriate? (1996) (8)
- Simultaneous 13N-Ammonia and gadolinium first-pass myocardial perfusion with quantitative hybrid PET-MR imaging: a phantom and clinical feasibility study (2019) (8)
- Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. (2010) (7)
- APPLICATION OF a GENE EXPRESSION‐BASED MODEL IN COMBINATION WITH FDG‐PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033) (2017) (7)
- Baseline SUVmax did not predict histological transformation in the phase 3 GALLIUM study in follicular lymphoma. (2020) (7)
- A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET. (2010) (7)
- Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma (2007) (7)
- NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA (2019) (7)
- Early Response : Results from ‘ Response Adapted Therapy in Advanced Hodgkin Lymphoma ’ ( RATHL ) ( CRUK / 07 / 033 ) (2018) (6)
- Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline (2022) (6)
- Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand (2019) (6)
- 18F-FDG-PET in Guided Dose-Painting with Intensity Modulated Radiotherapy in Oropharyngeal Tumours: A Phase I Study (FiGaRO). (2020) (5)
- New horizons in multimodality molecular imaging and novel radiotracers (2017) (5)
- Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy. (2019) (5)
- COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial (2020) (5)
- Ventilation and perfusion lung imaging - which nebulizer? (1995) (5)
- IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL (2021) (5)
- Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy/decortication in malignant pleural mesothelioma. (2012) (5)
- The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium (2019) (5)
- Role of PET imaging in adaptive radiotherapy for lymphoma. (2018) (5)
- Robustness and Generalizability of Deep Learning Synthetic Computed Tomography for Positron Emission Tomography/Magnetic Resonance Imaging–Based Radiation Therapy Planning of Patients With Head and Neck Cancer (2021) (5)
- Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma (2020) (4)
- Dose rate measurements combined with social behavior models enables estimation of potential radiation hazards to families of patients treated with radioiodine. (2000) (4)
- HL91, a new Tc-99m labelled agent with potential for identifying tumour hypoxia: Correlation with FDG PET (1996) (4)
- does Quantitative Pet-ct Predict Prognosis In Diffuse Large Bcell Lymphoma (dlbcl)? : 014 (2013) (4)
- Analysis of the Deauville criteria for the assessment of interim PET in advanced stage Hodgkin lymphoma patients enrolled in the IVS study part II: Reliability of score and concordance between reviewers (2012) (4)
- REVIEWARTICLE FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas (2017) (3)
- The value of the chest radiograph in reporting aerosol ventilation‐perfusion scans (1998) (3)
- FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma (2015) (3)
- Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
- Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT (2016) (3)
- A comparison of approaches to reduce respiratory motion artifacts in NH3 PET/CT imaging (2012) (3)
- Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation (2022) (3)
- 8. Twenty-four hour discharge for thyroid cancer patients treated with radioiodine (1993) (3)
- Guidance on the use of PET for treatment planning in radiotherapy clinical trials. (2019) (3)
- Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma (2021) (3)
- Are all ecological studies fallacious? Not necessarily. (1997) (3)
- Assessment of changes in dual-energy X-ray absorptiometry performance following a system upgrade. (1996) (2)
- Radiation dose rates post 131I therapy and advice to patients on discharge from hospital. (1997) (2)
- PO-0609: 18F-FDG-PET in Guiding Dose-painting with IMRT in Oropharyngeal Tumours (FiGaRO) - Early Results (2017) (2)
- Physiological uptake occurs in the thymus of young patients treated with radioiodine for thyroid carcinoma (1997) (2)
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical) (2022) (2)
- Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical) (2022) (2)
- The Role of Imaging in Radiotherapy for Hodgkin Lymphoma (2011) (2)
- A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia (2021) (2)
- Standardised PET-CT reporting for an international multicentre trial in lymphoma (RATHL) (2011) (2)
- Radiation protection issues. (1996) (2)
- Test-retest Repeatability and Interobserver Variation of Healthy Tissue Metabolism using FDG-PET/CT of the Thorax among Lung Cancer Patients (2022) (2)
- 4. Thymic uptake after 131I therapy for thyroid carcinoma: A trap for the unwary? (1997) (2)
- INTERNATIONAL VALIDATION STUDY OF INTERPRETATION RULES AND PROGNOSTIC ROLE OF INTERIM-PET SCAN IN ADVANCED STAGE HODGKIN LYMPHOMA (2011) (2)
- Consolidation Radiation Therapy Improves Outcome of Diffuse Large B-cell Lymphoma Independent of Pretreatment Prognosis or Response to Chemotherapy (2016) (2)
- The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World (2020) (2)
- When is PET not useful in the assessment of lymphoma? (2003) (2)
- Home reporting for the nuclear clinician? (1995) (2)
- PP-4-17 Use of positron emission and computed tomography in evaluation of brachial plexopathy in breast cancer patients (1996) (1)
- Comparison of Threshold-Based Segmentation Methods on Pre- and Post-Therapy PET Scans (2014) (1)
- ONGOING TRIALS (2013) (1)
- A case–control evaluation of pulmonary and extrapulmonary findings of incidental asymptomatic COVID-19 infection on FDG PET-CT (2021) (1)
- NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMA (2021) (1)
- Left ventricular dysfunction (2006) (1)
- Reply to: Laffon and Marthan “FDG PET for therapy monitoring in Hodgkin’s and non-Hodgkin’s lymphomas: qPET versus rPET” (2017) (1)
- Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study (2021) (1)
- Bone mineral densitometry in clinical practice (1995) (1)
- 65. Radiation protection advice after radioiodine therapy -an easier way! (1996) (1)
- Suboptimal use of inhaled aerosol therapy during mechanical ventilation in intensive therapy units in the UK and Ireland. (1998) (1)
- A one-hour walk-in service for wrist trauma imaging. (1999) (1)
- The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP (2015) (1)
- Reply to G. Keramida et al. (2015) (1)
- PET/MRI in Lymphoma (2018) (1)
- What Is the Optimal Definition of Bulk in Diffuse Large B-cell Lymphoma Patients Treated With RCHOP? (2015) (1)
- Robustness and generalizability of deep learning synthetic CT for PET/MRI-based radiotherapy planning of head and neck cancer patients (2021) (1)
- EP-1126: Target volume delineation of PET post one cycle of induction chemotherapy in oropharyngeal cancer (2018) (1)
- Analysis of the Deauville criteria for the assessment of interim PET in advanced stage Hodgkin lymphoma patients enrolled in the IVS study part I: Diagnostic accuracy and prognostic value (2012) (1)
- Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods (2018) (1)
- Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply. (2019) (1)
- Comparison Of Contrast-Enhanced Ct-Based Response With Pet Assessment After First-Line Therapy For Follicular Lymphoma In The Phase Iii Gallium Study (2017) (1)
- Clinical Nuclear Medicine 4th edition (2007) (1)
- Whole body applications of positron emission tomography in oncology (2001) (1)
- Can staging PET detect bone marrow involvement in lymphoma (1996) (1)
- Scan preparation for patients with type I diabetes treated with continuous sub-cutaneous insulin infusion (CSII) pumps (2019) (1)
- Reply to the letter (2002) (1)
- Is marrow biopsy staging for hd and dlbcl obsolete in the pet-ct era (2011) (1)
- Erratum to: Effect of Bayesian-penalized likelihood reconstruction on [13N]-NH3 rest perfusion quantification (2017) (1)
- Is perfusion lung scanning hazardous in pulmonary hypertension? (1995) (1)
- Evaluation of 3 registration methods for pre- and post-therapy PET/CT studies (2010) (1)
- RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS (2021) (1)
- The Impact of Interactive MRI-Based Radiologist Review on Radiotherapy Target Volume Delineation in Head and Neck Cancer (2023) (0)
- P22. Ten years of PET scanning kids with cancer (2003) (0)
- Comparison of the effects of the IDSC and COMAC-BME DXA standardisation methods (2006) (0)
- First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up. (2020) (0)
- EP-1149: Clinical Evaluation of attenuation correction in FDG-PET/MRI in a head and neck radiotherapy setup (2018) (0)
- Inhibition-a novel approach to treating CoronAry heart DiseAse ( CICADA ) : study protocol for a randomised controlled trial (2017) (0)
- Perfusion lung scanning in pulmonary hypertension: A reply (1995) (0)
- Preliminary results of a phase II study of brentuximab vedotin using a response adapted design for the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY) (2016) (0)
- EP-1155 Analysis of loco-regional failures in head and neck cancer after intensity-modulated radiation therapy (2015) (0)
- A pilot study of staging and follow‐up of patients with lymphoma with FDG PET (1995) (0)
- Interobserver variability in interim PET assessment in Hodgkin lymphoma—reasons and solutions (2023) (0)
- 83PRepeatability evaluation of PET/CT imaging using [18F]fluorothymidine (FLT) and [18F]fluorodeoxyglucose (FDG) in primary triple negative breast cancer (TNBC) (2015) (0)
- P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials (2022) (0)
- FDG and methionine positron emission tomography (PET) scanning in patients with HIV disease and cerebral pathology (1996) (0)
- Home reporting via standard telephone lines: A country road to the superhighway (1995) (0)
- Effect of Q.Clear reconstruction on [13N]-NH3 perfusion imaging in suspected cardiac sarcoidosis (2016) (0)
- Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study (2021) (0)
- The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma. (2022) (0)
- 82. Is there a need for unification of dual-energy X-ray absorptiometry (DXA) standardization techniques? (1996) (0)
- 64. Effect of reduced transmission scan times with segmentation in dedicated PET (2002) (0)
- Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials (2022) (0)
- OC-0351: Deep learning for rectal spacer stratification in prostate boost radiotherapy (2020) (0)
- LV dysfunction: Functional imaging (2007) (0)
- Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. (2023) (0)
- PO-1751: Effect of pseudoCT methods on dose-derived rectal toxicity prediction in MR-only prostate RT (2020) (0)
- Oxford Textbook of Nuclear Medicine (2013) (0)
- ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (2021) (0)
- Reply to LTE: Automated segmentation of TMTV in DLBCL patients: what about method measurement uncertainty? (2020) (0)
- The lateralising value of slow activity in temporal lobe epilepsy and its relation to the interictal cerebral glucose metabolism (1996) (0)
- Neural network dose prediction for rectal spacer stratification in dose‐escalated prostate radiotherapy (2022) (0)
- Can N2 disease be predicted by FDG uptake in the primary lung tumour or hilar lymphadenopathy (2009) (0)
- 85. Medium-term precision in DXA scanning: How quoted precision relates to clinical practice (1996) (0)
- A rare intravascular tumour diagnosed by endobronchial ultrasound (2016) (0)
- 3. Cost-effectiveness of PET in the selection of patients with ischaemic heart disease and impaired left ventricular function for surgery (2002) (0)
- Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy (2022) (0)
- Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy. (2008) (0)
- Baseline Metabolic Tumour Volume to Predict Outcome in Diffuse Large B Cell Lymphoma: Which Method? (2016) (0)
- External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL (2022) (0)
- 83. Which normal data set best fits our local population: A DXA survey (1996) (0)
- IN7 PET: staging, response assessment and open questions (2012) (0)
- Phagocytic labelling of white cells with 99Tcm‐colloid in suspected sepsis (1995) (0)
- Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial (2020) (0)
- Comparison of cardiac magnetic resonance imaging and positron emission tomography for the diagnosis and localization of coronary artery disease (2011) (0)
- 13. The value of the chest radiograph in reporting ventilation perfusion scans (1996) (0)
- Rheumatology (1990) (0)
- 14. Comparison of sestamibi, thallium, echocardiography and PET in the detection of hibernating myocardium: the STEP study (2002) (0)
- PO-0664: Outcome of radiotherapy for stage I and II follicular lymphoma in patients staged by 18 FDG PET-CT (2016) (0)
- Multicenter quantitative assessment of treatment response by FDG PET/CT (2014) (0)
- Can chest X-rays and ventilation/perfusion scans be interpreted reliably from personal computer screens? (1998) (0)
- Intractable hiccups causing avid FDG uptake in the muscles of respiration (2009) (0)
- Effects of sumatriptan on myocardial perfusion using 13NH3 PET (1995) (0)
- The 5 Th InTernaTIonal Workshop on posITron emIssIon Tomography In lymphoma Report on the 5 th International Workshop on Positron Emission Tomography in Lymphoma held in Menton , France , 19 – 20 September 2014 (2015) (0)
- Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after initial chemotherapy is not always required: subsidiary analysis of the UK NCRI RAPID study (2018) (0)
- Which normal DXA reference range should we use? (2006) (0)
- Contamination hazard due to iodine-131 therapy for thyrotoxicosis. (1999) (0)
- PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study (2021) (0)
- Principles and Practice of Positron Emission Tomography (2006) (0)
- Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin ' s Lymphoma (2016) (0)
- A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma (2022) (0)
- Medium term precision in DXA scanning: How quoted precision relates to clinical practice (2006) (0)
- P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma (2022) (0)
- FDG-PET in lymphoma (2014) (0)
- Assessment of spatial accuracy in indirect PET-CT radiotherapy planning: Staging versus dedicated planning PET-CT (2014) (0)
- A 1‐h walk‐in service for wrist fractures – a reality? (1995) (0)
- Comparative performance of the Norland XR 26 DEXA system using 2.2 and 2.3 software versions (1995) (0)
- 80. Ventilation lung imaging: which nebulizer? (1994) (0)
- An overview of nuclear medicine research in the UK and the landscape for clinical adoption (2021) (0)
- Reply to H.J.A. Adams et al and C. Kobe et al. (2019) (0)
- BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALS (2021) (0)
- Imaging techniques in the assessment of myocardial hibernation - Reply (2004) (0)
- Sumatriptan does not affect myocardial perfusion in healthy individuals (1995) (0)
- Running Head: PET-CT for staging and response in the RATHL trial (2016) (0)
- 118 High-resolution cardiac magnetic resonance perfusion imaging vs positron emission tomography for the detection and localisation of coronary artery disease (2011) (0)
- 186 Impact of integrated PET-CT on the selection of patients with malignant pleural mesothelioma for radical surgery (extrapleural pneumonectomy) (2006) (0)
- Survival from malignant pleural mesothelioma is predicted by FDG PET (2012) (0)
- Physiological uptake of F-18 fluoro-2-deoxyglucose by the laryngeal muscles with speech (1996) (0)
- 95. Staging PET can detect bone marrow involvement in lymphoma (1997) (0)
- Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity (2016) (0)
- Clinical Nuclear Medicine (2007) (0)
This paper list is powered by the following services:
Other Resources About Sally Barrington
What Schools Are Affiliated With Sally Barrington?
Sally Barrington is affiliated with the following schools:
